Dual Renin-Angiotensin System Blockade and Kidney Disease

Journal of the American College of Cardiology

Volumn 54, Issue 3, 2009, Pages 278-279

  Parving, Hans Henrik ^a   Brenner, Barry M ^a   McMurray, John J V ^a   de Zeeuw, Dick ^a   Haffner, Steven M ^a   Solomon, Scott D ^a   Chaturvedi, Nish ^a   Pfeffer, Marc A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALISKIREN; CREATININE; RAMIPRIL; TELMISARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGING; ALBUMINURIA; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DIALYSIS; ENZYMATIC ASSAY; GLOMERULUS CAPILLARY; GLOMERULUS FILTRATION RATE; HEART HEMODYNAMICS; HUMAN; HYDRAULIC CONDUCTIVITY; KIDNEY DISEASE; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; BLOOD; DRUG EFFECT; MORTALITY; NOTE; HEART FAILURE;

ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CREATININE; HUMANS; RENAL DIALYSIS; RENIN-ANGIOTENSIN SYSTEM; HEART FAILURE;

EID: 67649605057     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.02.074     Document Type: Letter

References (12)

1. Mann J.F., Schmieder R.E., McQueen M., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372 (2008) 547-553
2. Messerli F.H. The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point. J Am Coll Cardiol 53 (2009) 468-470
3. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
4. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
5. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008) 1547-1559
6. Lewis E., Hunsicker L., Bain R., and Rhode R. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329 (1993) 1456-1462
7. Ruggenenti P., Perna A., Gherardi G., et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354 (1999) 359-364
8. Klahr S., Levey A.S., Beck G.J., et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 330 (1994) 877-884
9. Palmer B.F. Renal dysfunction complicating the treatment of hypertension. N Engl J Med 347 (2002) 1256-1261
10. Kunz R., Friedrich C., Wolbers M., and Mann J.F.E. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Intern Med 148 (2008) 30-48
11. Sarafidis P.A., and Bakris G.L. Renin-angiotensin blockade and kidney disease. Lancet 372 (2008) 511-512
12. Parving H.-H., Brenner B.M., McMurray J., et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 24 (2009) 1663-1671